Consensus recommendations for resistance testing in the management of chronic hepatitis C virus infection: Public Health England HCV Resistance Group-Reference-Cited by-同舟云学术

Consensus recommendations for resistance testing in the management of chronic hepatitis C virus infection: Public Health England HCV Resistance Group

Published:2019-12 Issue:6 Volume:79 Page:503-512
ISSN:0163-4453
Container-title:Journal of Infection
language:en
Short-container-title:Journal of Infection

Author:

Bradshaw Daniel,Mbisa Jean L,Geretti Anna Maria,Healy Brendan J,Cooke Graham S,Foster Graham R,Thomson Emma C,McLauchlan John,Agarwal Kosh,Sabin Caroline,Mutimer David,Moss Peter,Irving William L,Barnes Ellie

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical)

Reference86 articles.

1. EASL Recommendations on Treatment of Hepatitis C 2018

2. HCV guidance: recommendations for testing, managing, and treating hepatitis C;Clin Infect Dis,2018

3. Global health sector strategy on viral hepatitis, 2016–2021: towards ending viral hepatitis 2016 [Available from:http://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-eng.pdf?sequence=1.

4. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy;Neumann;Science,1998

5. Effect of ribavirin on the mutation rate and spectrum of hepatitis C virus in vivo;Cuevas;J Virol,2009

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of 2 Novel Subtypes of Hepatitis C Virus Genotype 8 and a Potential New Genotype Successfully Treated With Direct Acting Antivirals;The Journal of Infectious Diseases;2024-05-08

2. Hepatitis C Virus Nonstructural Protein 3 Increases Secretion of Interleukin-1beta in HEK293T Cells with a Reconstructed NLRP3 Inflammasome;Molecular Biology;2023-10

3. Hepatitis C Virus Nonstructural Protein 3 Increases Secretion of Interleukin-1beta in HEK293T Cells with Reconstructed NLRP3 Inflammasome;Молекулярная биология;2023-09-01

4. Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for hepatitis C in a single-arm mechanistic pilot study;eLife;2023-01-09

5. Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for Hepatitis C: a single arm mechanistic pilot study;2022-08-17